Clinical Trials

300 enrolled

Other solid neoplasm

Solid Tumors

NCT04879329 2026-04-21

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

372 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03485209 2026-04-20

innovaTV 207

GastrointestinalHead & NeckThoracic

350 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07252739 2026-04-17

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

130 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT04701476 2026-04-16

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

110 enrolled

GastrointestinalThoracic

Lung Neoplasms, Colorectal Neoplasms

NCT07475806 2026-04-15

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

240 enrolled

Muscle-invasive Bladder Cancer

NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

BreastGastrointestinalHead & NeckThoracic

329 enrolled 23 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT05446298 2026-04-13

PRESERVE-004

58 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06961006 2026-04-13

INTerpath-012

160 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT07221474 2026-04-13

INTerpath-13

180 enrolled

Squamous Non-small Cell Lung Cancer

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

53 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT05077709 2026-04-08

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

63 enrolled 18 charts

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT06099782 2026-04-08

MK-3475A-F11

DermatologicGenitourinaryThoracic

147 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT06984328 2026-04-08

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

1 enrolled

Phase 2 Not yet recruiting

Melanoma, Recurrence

NCT07415031 2026-04-08

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

170 enrolled

Other solid neoplasm

Solid Tumors

NCT05217446 2026-04-07

SEAMARK

107 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07511972 2026-04-06

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Phase 2 Withdrawn

CRC

NCT03505320 2026-04-03

ILUSTRO

143 enrolled

Neoplasms, Stomach Neoplasms

NCT07353957 2026-04-02

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

180 enrolled

Lung Neoplasms

NCT03899155 2026-04-01

Pan Tumor Rollover Study

1,500 enrolled

Tumor-Agnostic

Neoplasms

NCT06788912 2026-03-31

MK-3475-01E

60 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT04736173 2026-03-30

ARC-10

169 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04895722 2026-03-30

MK-1308A-008

302 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT06008093 2026-03-30

TRITON

100 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07486817 2026-03-23

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

60 enrolled

Lung Neoplasms

NCT06036836 2026-03-19

MK-4280A-010

163 enrolled

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

378 enrolled 15 charts 2 FDA

Uveal Melanoma, Melanoma

NCT03547973 2026-03-16

TROPHY U-01

827 enrolled 2 FDA

Metastatic Urothelial Cancer

NCT04609566 2026-03-16

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

DermatologicHead & NeckThoracic

161 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05852691 2026-03-16

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

83 enrolled

Breast Neoplasms

NCT06797635 2026-03-13

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

372 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07452224 2026-03-12

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05926960 2026-03-09

PORTSIDE

Phase 2 Terminated

38 enrolled

Melanoma, Skin Neoplasms

NCT07264816 2026-03-05

A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC

80 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT04191135 2026-03-03

KEYLYNK-009

462 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT07098988 2026-02-27

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Other solid neoplasmThoracic

107 enrolled

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

40 enrolled 67 charts

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04379596 2026-02-23

DG-03

450 enrolled

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT03407144 2026-02-19

MK-3475-667

340 enrolled

Lymphoid

Hodgkin Disease

NCT05005442 2026-02-19

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Other hematologic neoplasm

192 enrolled 22 charts

Hematologic Neoplasms

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06731907 2026-02-18

MK-3475-01G

90 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06041802 2026-02-17

MK-3475A-E39

19 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Squamous Cell

NCT05805501 2026-02-12

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

199 enrolled

Carcinoma, Renal Cell

NCT05186974 2026-02-11

EVOKE-02

193 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05775289 2026-02-11

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

182 enrolled 35 charts

Carcinoma, Non-Small-Cell Lung

NCT06682806 2026-02-02

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Phase 2 Terminated

6 enrolled

Esophageal Neoplasms, Neoplasm Metastasis

NCT05814666 2026-01-30

PEMDA-HN

Phase 2 Terminated

69 enrolled 21 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05816252 2026-01-27

MK-2870-003

356 enrolled